Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$2.28 USD

2.28
7,179,830

+0.17 (8.06%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $2.26 -0.02 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Precision (DTIL) Inks Deal With Tiziana for Cancer Candidate

by Zacks Equity Research

Precision (DTIL) signs an exclusive license agreement with Tiziana to explore the latter's fully human anti-CD3 mAb, foralumab, for treating various cancer indications. Stock up.

Zacks Equity Research

Here's Why Momentum Investors Will Love Spero Therapeutics, Inc. (SPRO)

by Zacks Equity Research

Does Spero Therapeutics, Inc. (SPRO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Stealth (MITO) Files NDA for Ultra-Rare Disease Candidate

by Zacks Equity Research

Stealth BioTherapeutics (MITO) files a new drug application for elamipretide to the FDA for the treatment of Barth syndrome, an ultra-rare genetic condition.

Zacks Equity Research

Bristol Myers' (BMY) sBLA for Orencia Gets FDA Priority Review

by Zacks Equity Research

The FDA accepts Bristol Myers' (BMY) sBLA for Orencia under a priority review to prevent moderate to severe acute graft versus host disease. A verdict is pending on Dec 23, 2021.

Zacks Equity Research

Apellis' (APLS) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Apellis (APLS) reports a wider-than-expected loss for the second quarter of 2021. Revenues too miss expectations.

Zacks Equity Research

Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q1

by Zacks Equity Research

Immunovant's (IMVT) earnings miss estimates in first-quarter fiscal 2022 (ended Jun 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.

Zacks Equity Research

bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

by Zacks Equity Research

bluebird (BLUE) reports a wider-than-expected loss in second-quarter 2021 and also misses revenue estimates. Shares down in pre-market trading as FDA places clinical hold eli-cel.

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 18.18% and 101.88%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.

Zacks Equity Research

Editas (EDIT) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the second quarter of 2021 while revenues miss estimates. Focus remains on the development of CRISPR gene-editing candidate, EDIT-101.